☆ 4.6 Meeting Abstract

A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.

MOLECULAR CANCER THERAPEUTICS (2013)

Get Full Text
Add to Collection

Journal

MOLECULAR CANCER THERAPEUTICS
Volume 12, Issue 11, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.TARG-13-B48

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.